After a string of global scandals over toxic Indian cough syrups linked to child deaths abroad, the Central Drugs Standard Control Organisation (CDSCO) has drawn a hard line, all drug manufacturers must comply with global Good Manufacturing Practices (GMP) by January 1, 2026, or face closure.

No further extensions will be granted.

FINAL DEADLINE FOR NON-COMPLIANT UNITS

The CDSCO’s latest order targets 1,470 pharmaceutical manufacturing units with an annual turnover below Rs 250 crore that had been granted extra time to meet revised Schedule M GMP standards.

These smaller facilities were earlier given until January 1, 2026, provided they applied for an extension before May 2025. The regulator has now made it clear that no more leeway will be allowed beyond that date.

Out of India’s 5,3

See Full Page